Lantheus Holdings, Inc. $LNTH Position Trimmed by William Blair Investment Management LLC

William Blair Investment Management LLC lessened its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 9.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 522,177 shares of the medical equipment provider’s stock after selling 52,504 shares during the quarter. William Blair Investment Management LLC’s holdings in Lantheus were worth $34,751,000 at the end of the most recent quarter.

Other institutional investors have also made changes to their positions in the company. Quantbot Technologies LP acquired a new stake in shares of Lantheus during the 3rd quarter valued at about $1,847,000. American Assets Inc. acquired a new stake in shares of Lantheus during the 3rd quarter valued at about $872,000. Assetmark Inc. lifted its holdings in shares of Lantheus by 20.1% during the 3rd quarter. Assetmark Inc. now owns 118,503 shares of the medical equipment provider’s stock valued at $6,078,000 after buying an additional 19,844 shares during the last quarter. Vanguard Group Inc. lifted its holdings in shares of Lantheus by 1.7% during the 3rd quarter. Vanguard Group Inc. now owns 6,952,418 shares of the medical equipment provider’s stock valued at $356,590,000 after buying an additional 115,338 shares during the last quarter. Finally, Y Intercept Hong Kong Ltd acquired a new stake in shares of Lantheus during the 3rd quarter valued at about $3,866,000. 99.06% of the stock is currently owned by institutional investors and hedge funds.

Lantheus Price Performance

LNTH opened at $103.00 on Monday. The business has a 50 day moving average price of $83.62 and a 200 day moving average price of $71.86. Lantheus Holdings, Inc. has a twelve month low of $47.25 and a twelve month high of $103.89. The company has a debt-to-equity ratio of 0.47, a quick ratio of 2.64 and a current ratio of 2.83. The firm has a market cap of $6.71 billion, a P/E ratio of 24.82 and a beta of -0.08.

Lantheus (NASDAQ:LNTH) last posted its earnings results on Thursday, May 7th. The medical equipment provider reported $1.46 earnings per share for the quarter, topping the consensus estimate of $1.25 by $0.21. Lantheus had a return on equity of 29.32% and a net margin of 18.05%.The firm had revenue of $377.33 million during the quarter, compared to analyst estimates of $354.48 million. During the same period in the previous year, the company earned $1.53 EPS. The company’s revenue for the quarter was up 1.2% on a year-over-year basis. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. Research analysts forecast that Lantheus Holdings, Inc. will post 4.41 EPS for the current year.

Analyst Ratings Changes

Several brokerages have recently issued reports on LNTH. Citigroup reiterated an “outperform” rating on shares of Lantheus in a report on Friday, May 8th. B. Riley Financial reiterated a “buy” rating on shares of Lantheus in a report on Friday, May 1st. Truist Financial reiterated a “buy” rating and set a $115.00 price target (up from $98.00) on shares of Lantheus in a report on Monday, May 11th. William Blair reiterated an “outperform” rating on shares of Lantheus in a report on Tuesday, March 17th. Finally, Wall Street Zen lowered Lantheus from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 9th. Eight analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $99.71.

Lantheus Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.